Revefenacin Patent Expiration

Revefenacin is Used for maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). It was first introduced by Mylan Ireland Ltd in its drug Yupelri on Nov 9, 2018.


Revefenacin Patents

Given below is the list of patents protecting Revefenacin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Yupelri US10106503 Biphenyl compounds useful as muscarinic receptor antagonists Mar 10, 2025 Mylan Ireland Ltd
Yupelri US10343995 Biphenyl compounds useful as muscarinic receptor antagonists Mar 10, 2025 Mylan Ireland Ltd
Yupelri US10550081 Crystalline freebase forms of a biphenyl compound Jul 14, 2030 Mylan Ireland Ltd
Yupelri US11008289 Crystalline freebase forms of a biphenyl compound Jul 14, 2030 Mylan Ireland Ltd
Yupelri US11247969 Biphenyl compounds useful as muscarinic receptor antagonists Mar 10, 2025 Mylan Ireland Ltd
Yupelri US11484531 Methods for treating chronic obstructive pulmonary disease Oct 23, 2039 Mylan Ireland Ltd
Yupelri US11691948 Crystalline freebase forms of a biphenyl compound Jul 14, 2030 Mylan Ireland Ltd
Yupelri US11858898 Crystalline freebase forms of a biphenyl compound Jul 14, 2030 Mylan Ireland Ltd
Yupelri US7288657 Biphenyl compounds useful as muscarinic receptor antagonists Dec 23, 2025 Mylan Ireland Ltd
Yupelri US7491736 Biphenyl compounds useful as muscarinic receptor antagonists Mar 10, 2025 Mylan Ireland Ltd
Yupelri US7521041 Biphenyl compounds useful as muscarinic receptor antagonists Mar 10, 2025 Mylan Ireland Ltd
Yupelri US7550595 Biphenyl compounds useful as muscarinic receptor antagonists Mar 10, 2025 Mylan Ireland Ltd
Yupelri US7585879 Biphenyl compounds useful as muscarinic receptor antagonists Mar 10, 2025 Mylan Ireland Ltd
Yupelri US7910608 Biphenyl compounds useful as muscarinic receptor antagonists Mar 10, 2025 Mylan Ireland Ltd
Yupelri US8034946 Biphenyl compounds useful as muscarinic receptor antagonists Mar 10, 2025 Mylan Ireland Ltd
Yupelri US8053448 Biphenyl compounds useful as muscarinic receptor antagonists Mar 10, 2025 Mylan Ireland Ltd
Yupelri US8273894 Biphenyl compounds useful as muscarinic receptor antagonists Mar 10, 2025 Mylan Ireland Ltd
Yupelri US8541451 Crystalline freebase forms of a biphenyl compound Aug 25, 2031 Mylan Ireland Ltd
Yupelri US9765028 Crystalline freebase forms of a biphenyl compound Jul 14, 2030 Mylan Ireland Ltd


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Revefenacin's patents.

Given below is the list recent legal activities going on the following patents of Revefenacin.

Event Date Patent/Publication
Patent litigations
Email Notification 03 May, 2024 US7585879
Change in Power of Attorney (May Include Associate POA) 03 May, 2024 US7585879
Email Notification 25 Apr, 2024 US7288657
Change in Power of Attorney (May Include Associate POA) 25 Apr, 2024 US7288657
Payment of Maintenance Fee, 12th Year, Large Entity 25 Mar, 2024 US8273894
Notice of Final Determination -Election Required 22 Mar, 2024 US7585879
Notice of Final Determination -Election Required 22 Mar, 2024 US7288657
Recordation of Patent eCertificate of Correction 20 Feb, 2024 US11858898
Mail Patent eCofC Notification 20 Feb, 2024 US11858898
Email Notification 20 Feb, 2024 US11858898



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳